I'll second that Guts. With specialty revenues increasing from $494K in March (first full month of operations) to $958K in April to $1.6 million in May, I'd say that not only is SCRC a good OTC pick for the week, it will also be a solid MVP contender for 2014, 2015, and beyond as it develops and matures all three business models (e.g., specialty pharmacy, RapiMeds - Oral Delivery Technology, and PIMD/WholesaleRx - Drug Supply Management & Distribution to 23K-plus small and independent pharmacies). I predict $50 million in revenues by 2015. This is a great turnaround story, and the sp has yet to reflect the value here.